Normal cytology

LSIL

HSIL

Cervical cancer

HPV_prevalence

Normal cytology

LSIL

HSIL

Cervical cancer

Findings

HPV Prevalence:

Among the continents, Oceania exhibits the highest median prevalence of HPV infection, with a median value of approximately 42.77%. In contrast, Africa demonstrates the lowest median prevalence of HPV16 and HPV18, with a median value of approximately 33.62%. The application of the Kruskal-Wallis test reveals a statistically significant difference in the prevalence of HPV infection across continents, as indicated by a p-value of approximately. This finding strongly suggests that the observed disparities in median values are unlikely to occur by random chance, emphasizing the presence of genuine variations in HPV prevalence among different continents.

Normal Cytology:

Among the continents, Oceania exhibits the highest median prevalence of HPV infection, with a median value of 8.30%. This prevalence is notably higher than what is observed in other continents. In contrast, Africa demonstrates the lowest median prevalence of HPV infection, recorded at 3.80%. When considering the error bars, which represent the 95% confidence intervals, the widest range is observed in the Americas and Europe. This indicates greater variability in the estimates of HPV prevalence within these continents compared to others, suggesting potential regional differences or inconsistencies in data collection.

LSIL:

The median prevalence of HPV in LSIL cases is highest in Europe and Oceania, with a median value of 27.10%. This prevalence surpasses that observed in other continents by a small margin. In contrast, Asia exhibits the lowest prevalence of HPV at 21.20%, followed by Africa at 24.90%. Utilizing the Kruskal-Wallis test, we establish a statistically significant difference in the prevalence of HPV infection across continents, indicating genuine variations among them. Further pairwise comparisons, considering adjusted p-values, unveil significant disparities in prevalence rates among continents. Notably, Europe and Oceania emerge as having significantly higher prevalence rates compared to other continents.

HSIL:

Oceania stands out among the continents with the highest median prevalence of HPV infection in HSIL cases, recording a median value of 59.10%. The Americas closely trail behind with a median prevalence of 56.90%. Africa exhibits the lowest median prevalence of HPV at 38.60%, followed by Asia at 42.10%. Utilizing the Kruskal-Wallis test, we establish a statistically significant difference in the prevalence of HPV infection across continents. Further pairwise comparisons, considering adjusted p-values, uncover significant disparities in prevalence rates among certain continents. Notably, the comparison between Africa and Oceania reveals a significant difference with an adjusted p-value, indicating substantial variations in HPV prevalence between these continents.

ICC:

Oceania exhibits the highest median prevalence of HPV infection in cervical cancer cases, recording a median value of 76.60%, closely followed by Europe at 74.0%. This prevalence exceeds that observed in other continents. Conversely, Africa displays the lowest median prevalence among the examined continents, with a median value of 67.20%. These findings highlight significant variations in HPV prevalence across different continents, emphasizing the importance of comprehensive research to elucidate the contributing factors and establish effective strategies for prevention, screening, and treatment in each affected region.

Normal cytology

LSIL

HSIL

Cervical cancer

Findings

Normal Cytology

In the African countries sampled, the median value of HPV prevalence in normal cytology cases is approximately 3.8%, as depicted by the median line on the plot. Most countries exhibit a low prevalence rate, as evidenced by a notable cluster of data points positioned towards the lower end of the HPV prevalence scale. However, several countries, including Guinea, Kenya, Mozambique, Benin, and Tunisia, demonstrate higher prevalence rates. The extremely low Wilcoxon p-value (1.225e-10) associated with the distribution of HPV prevalence in normal cytology cases indicates a statistically significant finding. This strongly suggests that the observed distribution is not a result of random chance but rather indicates the presence of underlying factors or patterns that contribute to HPV prevalence rates across these countries.

LSIL:

In the African countries included in the sample, the median percentage of HPV prevalence in LSIL cases is approximately 24.90%. There is notable variation in HPV prevalence among these countries, with the majority of data points clustering around the median value. However, Senegal, displays significantly higher prevalence rates. The Wilcoxon p-value is remarkably low (p = 4.96e-11), indicating a statistically significant difference in HPV prevalence across the sampled countries. This finding highlights genuine disparities in HPV prevalence rates among these nations.

HSIL:

The median percentage of HPV prevalence in HSIL cases among the sampled African countries is approximately 38.60%. Ethiopia stands out with a significantly higher percentage of HPV prevalence in HSIL cases, reaching 63%, followed by Tanzania, Kenya, and Senegal. Conversely, Zimbabwe, Guinea, Nigeria, and South Africa exhibit the lowest HPV prevalence in HSIL cases. The majority of data points cluster around the median value, indicating that, for most countries included in the study, the HPV prevalence in HSIL cases aligns with the median percentage. However, it is crucial to acknowledge the variation in prevalence rates among countries and investigate the underlying factors contributing to the observed differences.

ICC:

Among the sampled African countries, the median percentage of HPV prevalence in cervical cancer cases is approximately 67.20%. A broad range of HPV prevalence percentages is observed across these countries, with some recording values as low as 10% (e.g., Senegal) and others reaching as high as 98% (e.g., Sudan). While there is notable variability in HPV prevalence percentages, the majority of data points cluster around the median value of 67%, suggesting that, for most countries in this sample, the HPV prevalence in cervical cancer cases falls within this range.

Normal cytology

LSIL

HSIL

Cervical cancer

Findings

Normal Cytology:

Normal Cytology:

The median HPV prevalence in normal cytology cases among the surveyed countries is 4.50%. Cuba stands out among the countries depicted on the graph, displaying the highest HPV prevalence at 39%, followed by Honduras. The majority of countries included in the study exhibit an HPV prevalence below 10%, indicating a lower prevalence rate in normal cytology cases for these countries. These findings underscore the significance of ongoing monitoring and preventive measures to effectively manage HPV infections and mitigate the risk of progression to abnormal cytology and cervical cancer.

LSIL:

The data reveals a wide range of HPV prevalence in LSIL cases, with some countries exhibiting prevalence rates close to 5%, while Colombia shows an exceptionally high HPV prevalence of 80%. This substantial variability suggests variations in the incidence or detection of HPV-associated LSIL across different geographical areas. Certain countries stand out with particularly high HPV prevalence in LSIL cases. These findings may indicate unique epidemiological patterns, differences in healthcare practices, or variations in reporting mechanisms specific to those areas. The provided Wilcoxon rank statistic (630.00) and the associated p-value (≈ 1.63e-07) demonstrate a statistically significant difference in HPV prevalence between the countries being compared.

HSIL: The median value of HPV prevalence in HSIL cases among the sampled countries is 56.90%. The spread of data points along the x-axis indicates variations in the percentage of HPV prevalence from country to country. There is a wide range of HPV prevalence in HSIL cases observed among the countries, with the lowest prevalence around 32% and the highest close to 73%. This significant variability suggests notable differences in HPV prevalence in HSIL cases across different countries in Latin America and the Caribbean.

Notably, some countries such as Chile, Canada, and Venezuela exhibit higher prevalence rates, which may be of particular interest for public health interventions. These countries could benefit from targeted strategies aimed at prevention, early detection, and treatment of HSIL cases associated with HPV. On the other hand, Cuba, Jamaica, and Nicaragua show a lower prevalence of HPV in HSIL cases. These findings highlight the importance of tailored approaches to address the varying HPV prevalence and associated risks in different countries within the region.

ICC:

The median percentage of HPV prevalence in cervical cancer cases across the sampled countries is approximately 68.20%. There is a wide range of HPV prevalence percentages observed among the countries, with lower values noted in countries like Ecuador and Bolivia. On the other hand, higher HPV prevalence in cervical cancer cases is observed in countries such as Chile, Venezuela, Argentina, Canada, and the USA. The Wilcoxon rank sum test confirms that the differences in HPV prevalence among the sampled countries are statistically significant. This highlights the importance of understanding and addressing the varying HPV prevalence rates in cervical cancer cases in different countries, emphasizing the need for comprehensive prevention, screening, and treatment strategies to combat the burden of cervical cancer.

Normal cytology

LSIL

HSIL

Cervical cancer

Findings

Normal Cytology:

In the listed countries, the prevalence of HPV in normal cytology cases displays significant variation, spanning from minimal occurrences (close to 0%) to higher rates reaching approximately 7%. It is worth noting that a group of countries, potentially sharing geographical proximity or similar healthcare practices, exhibits considerably elevated HPV prevalence rates. The statistical analysis conducted on the data utilizes the Wilcoxon rank test, resulting in a p-value of approximately 2.05e-09. This exceptionally low p-value indicates strong statistical evidence supporting the existence of significant disparities in HPV prevalence among the countries. This finding underscores the importance of understanding the underlying factors contributing to these variations and tailoring preventive and screening measures accordingly to effectively manage and reduce the burden of HPV infections.

LSIL:

The prevalence of HPV in cases of LSIL shows a wide range among the listed countries. The rates range from nearly 10% in Japan to approximately 80% in Myanmar, indicating substantial variability in the occurrence of HPV-associated LSIL across different geographical regions. The median HPV prevalence in LSIL cases across the sampled countries is reported as 21.20%. This suggests that while some countries exhibit notably high prevalence rates, the typical prevalence for this group of countries is around one-fifth of LSIL cases being HPV-associated. Certain countries demonstrate remarkably high HPV prevalence in LSIL cases. For instance, Myanmar exhibits a prevalence rate close to 80%, which significantly surpasses rates observed in most other countries within the dataset. This finding may indicate the necessity for targeted public health interventions in these outlier countries to address the heightened burden of HPV-associated LSIL.

HSIL:

The vertical line positioned at approximately 42.10% represents the median HPV prevalence in HSIL cases across the sampled countries. The data points are distributed across a wide range, with the majority of countries exhibiting HPV prevalence rates between 27% and 70% in HSIL cases. Notably, Israel, Iran, and India display higher prevalence rates compared to other countries in the dataset. On the other hand, Thailand, Turkey, and Kuwait show lower prevalence rates in HSIL cases. This variation in HPV prevalence highlights the differences in the burden of HPV-associated HSIL across different countries. Understanding the factors contributing to these variations can help in implementing targeted interventions, such as HPV vaccination programs and improved screening strategies, to effectively manage and reduce the impact of HSIL cases associated with HPV.

ICC:

The median HPV prevalence in ICC (invasive cervical cancer) cases is reported as 68.90%. Jordan, Malaysia, Syria, Pakistan, and Indonesia show a high prevalence of HPV in ICC cases, while Mongolia, Japan, Philippines, and Iran exhibit a low prevalence. The data points predominantly cluster towards the lower end of the HPV prevalence scale, with a majority of the countries displaying prevalence rates below 70%. However, as the prevalence increases, there is noticeable variability in the numerical value of cervical cancer cases among countries, suggesting potential differences in the burden of cervical cancer in countries with higher HPV prevalence.

Several countries demonstrate exceptionally high HPV prevalence rates exceeding 80%. These countries highlight a concerning pattern where a substantial proportion of cervical cancer cases in these regions are associated with HPV infection. This finding underscores the need for targeted medical interventions, such as HPV vaccination programs and improved screening and treatment strategies, or further exploration into the underlying factors contributing to these elevated prevalence rates. Addressing the high burden of HPV-associated cervical cancer cases in these countries is crucial for reducing the impact of the disease and improving women’s health outcomes.

Normal cytology

LSIL

HSIL

Cervical cancer

Findings

Normal Cytology:

There is a wide range of HPV prevalence in normal cytology cases among the countries presented. Some countries have very low prevalence rates, close to 0%, while others have rates that are significantly higher, approaching 18%. This suggests that there are substantial differences in HPV prevalence across these countries, which could be due to various factors such as differences in vaccination rates, screening practices, or sexual health education. The median line shows that the median HPV prevalence in normal cytology cases among the sampled countries is around 3.8%. This median value provides a central tendency measure of the HPV prevalence across the countries, indicating that half of the countries have a prevalence below this value and half above.

LSIL:

The median HPV prevalence in LSIL cases across the observed countries is 27.10%. The Wilcoxon rank sum test suggests that there is a statistically significant difference in HPV prevalence between the countries being compared. The distribution of HPV prevalence in LSIL cases is skewed towards the lower end, with some countries having a prevalence below the median, and a few countries with exceptionally high prevalence rates.

HSIL:

There is a wide variation in HPV prevalence in HSIL cases across different European countries. The prevalence ranges from below 20% to nearly 80%, indicating significant disparities in HPV infection rates associated with high-grade lesions. Some countries such as Ireland, Switzerland, Netherlands, and Slovenia exhibit a high prevalence of HPV in HSIL cases, while others like Croatia and Norway demonstrate a comparatively lower prevalence. The median HPV prevalence in HSIL cases among the countries represented is marked by the blue dashed line, which appears to be at approximately 54.50%. This suggests that half of the countries have an HPV prevalence in HSIL cases below this value and half above.

ICC:

The countries at the top of the plot, such as Hungary, Luxembourg, and Finland, show a high percentage of HPV prevalence in cervical cancer cases. This suggests that HPV is a significant factor in cervical cancer in these countries. The blue dashed line indicates the median value of HPV prevalence among the countries listed. The median appears to be around 74%, which means that half of the countries have an HPV prevalence in cervical cancer cases that is above this value and half below.

Normal cytology

LSIL

HSIL

Cervical cancer

Findings

Normal cytology

There is a wide range of HPV prevalence in normal cytology cases across the Pacific region. Australia shows the highest prevalence rate, which is significantly higher than the other countries listed. The median HPV prevalence rate in normal cytology cases among the countries listed is 8.30%. This indicates that half of the countries have a prevalence rate below this value and the other half above it.

LSIL:

The HPV prevalence in LSIL cases is relatively consistent across the Pacific Island countries and territories, with a median value of approximately 27.10%. The interquartile range (IQR) is very narrow, indicating that the majority of the countries have a prevalence rate close to the median, suggesting low variability in HPV prevalence among these countries in LSIL cases. These findings suggest a consistent pattern of HPV prevalence in LSIL cases across the surveyed Pacific Island countries and territories, with little variation and a statistically significant result from the Wilcoxon test.

HSIL:

The HPV prevalence in HSIL cases varies across the countries, with the lowest observed values around 50% and the highest just above 70%. This indicates a relatively high prevalence of HPV in HSIL cases across these countries. Australia stands out with a notably lower prevalence of HPV in HSIL cases compared to other countries listed. This could indicate differences in HPV infection rates, screening practices, or healthcare interventions. While Fiji and New Zealand show high prevalence rates above 65%. The median HPV prevalence in HSIL cases is approximately 59.10%. This suggests that more than half of the HSIL cases in these Pacific countries have an HPV prevalence rate around this value.

ICC:

Papua New Guinea stands out with the highest HPV prevalence in cervical cancer cases among the countries listed, with a prevalence rate that appears to be close to 84%. This suggests that HPV is a major contributing factor to cervical cancer in this country. There is considerable variability in HPV prevalence rates among the countries in Oceania. This indicates that there may be diverse factors at play, such as differences in vaccination rates, screening practices, or sexual health education. The median HPV prevalence rate across the countries shown is approximately 76.60%. This median value suggests that over half of the countries have an HPV prevalence rate in cervical cancer cases that is quite high, emphasizing the need for effective HPV vaccination and screening programs in the region.